MABPHARM-B: (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807(2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) CHANGE IN USE OF PROCEEDS

HKEX · Mar 1, 2021 22:49

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

邁博藥業-B：(1) 有關收購CMAB807之須予披露及關連交易 (2) 有關臨床試驗協議及CDMO協議之持續關連交易 及 (3) 變更所得款項用途

MABPHARM-B: (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807(2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) CHANGE IN USE OF PROCEEDS

Risk Disclaimer

Statement

邁博藥業-B：(1) 有關收購CMAB807之須予披露及關連交易 (2) 有關臨床試驗協議及CDMO協議之持續關連交易及 (3) 變更所得款項用途